Literature DB >> 23063294

Impaired impulse control is associated with a 5-HT2A receptor polymorphism in schizophrenia.

Hui-Chun Tsuang1, Wei J Chen, Sheng-Hsiang Lin, Teng-Yi Chen, Yi-Lin Chang, Kuo-Hao Huang, Hsien-Yuan Lane.   

Abstract

The impact of the serotonin2a (5-HT2A) receptor gene on the pathophysiology of schizophrenia is inconclusive despite accumulating evidence implicating the 5-HT2A receptor. To simplify the complexity of genetic analysis, we used an endophenotype approach. The relationship between Continuous Performance Test (CPT) performance and 5-HT2A receptor gene variance was examined. Both patients with schizophrenia (n=255) and healthy volunteers (n=380) were recruited. All were genotyped for the -1438A/G polymorphism and assessed with the CPT. The Positive and Negative Syndrome Scale and the Scale for the Assessment of Negative Symptoms were used to evaluate patients' clinical symptoms. The distribution of the 5-HT2A genotypes between patients and healthy controls was similar. Impulse control in schizophrenic patients, assessed with the false-alarm rate of the CPT, differed significantly between those with different 5-HT2A genotypes. We hypothesize that the 5-HT2A receptor gene is a modifier gene of schizophrenia and suggest that additional studies are warranted.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063294     DOI: 10.1016/j.psychres.2012.09.038

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  2 in total

1.  Prediction of functional outcomes of schizophrenia with genetic biomarkers using a bagging ensemble machine learning method with feature selection.

Authors:  Eugene Lin; Chieh-Hsin Lin; Hsien-Yuan Lane
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

Review 2.  Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.

Authors:  William E Fantegrossi; Catheryn D Wilson; Michael D Berquist
Journal:  Drug Metab Rev       Date:  2018-01-31       Impact factor: 4.518

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.